Related Experiment Videos
[Systemic treatment for hepatocellular carcinoma].
H C Spangenberg1, I Zuber-Jerger, R Thimme
1Abteilung Innere Medizin II, Medizinische Universitätsklinik Albert-Ludwigs-Universität Freiburg, Germany.
Zentralblatt Fur Chirurgie
|December 12, 2003
Summary
Hepatocellular carcinoma (HCC) treatments are evolving, with transarterial chemoembolisation (TACE) showing survival benefits. Future therapies may include immunotherapy and targeted agents for better hepatocellular carcinoma management.
Area of Science:
- Hepatology
- Medical Oncology
- Cancer Research
Background:
- Hepatocellular carcinoma (HCC) is a prevalent global malignancy.
- Numerous pharmacological treatments have been explored for HCC management.
Purpose of the Study:
- To review current and emerging treatment strategies for hepatocellular carcinoma.
- To assess the efficacy of various interventions in HCC therapy.
Main Methods:
- Review of existing literature on HCC pharmacological treatments.
- Analysis of clinical investigations into novel HCC therapies.
Main Results:
- Transarterial chemoembolisation (TACE) monotherapy or combined with pravastatin demonstrated survival benefits in selected HCC patients.
- Emerging strategies like immunotherapy and antiangiogenic agents are under investigation for future HCC treatment.
Conclusions:
- Current treatments offer survival benefits for specific HCC patient groups.
- Future HCC therapies are likely to incorporate novel agents and approaches for improved outcomes.